Form 4: Innoviva Officer Matthew Ronsheim Reports Share Withholding for Tax Obligations
SEC Form 4 Filing
Matthew Ronsheim, an officer at Innoviva, Inc., reports the withholding of shares to cover income tax obligations related to equity grants.
Summary
- On May 20, 2024, Matthew Ronsheim, President of Innoviva Specialty Therapeutics, had 268 common stock shares withheld by Innoviva, Inc.
- The withholding was to satisfy income tax obligations associated with the quarterly vesting of previously granted employee equity grants.
- Following the transaction, Ronsheim directly owns 40,510 shares of Innoviva, Inc. common stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a routine transaction related to tax obligations on equity compensation. It doesn't convey any positive or negative sentiment about the company's performance or prospects.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and tax obligations, common in publicly traded companies. It provides transparency into insider transactions but doesn't necessarily indicate a significant shift in the company's outlook.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine administrative matter related to executive compensation.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of share withholding transaction. |
| 05/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.